ALKEM:NSE-Alkem Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 3,394.70

Change

0.00 (0.00)%

Market Cap

INR 406.46B

Volume

0.10M

Avg Analyst Target

INR 3,434.00 (+1.16%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alkem Laboratories Limited, a pharmaceutical company, develops, manufactures, and sells pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain relief/analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. Alkem Laboratories Limited was founded in 1973 and is headquartered in Mumbai, India. Address: Devashish Building, Mumbai, India, 400013

Company Website : http://www.alkemlabs.com

Address : Devashish Building, Mumbai, India, 400013

Employees : 14,331

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.34

52 Week High : 3,558.90

52 Week Low : 2,391.79

200 Day Moving Average : 2,957.89

50 Day Moving Average : 3,237.54

Shares Held By Insiders : 77.86%

Shares Held by Institutions : 15.35%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

 INR1,667.53B 57.44 31.75
DIVISLAB:NSE Divi's Laboratories Limited

N/A

 INR1,280.40B 64.52 43.09
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

 INR898.51B 52.28 22.27
CADILAHC:NSE Cadila Healthcare Limited

N/A

 INR630.62B 29.56 20.96
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

 INR564.49B 10.58 6.61
LUPIN:NSE Lupin Limited

N/A

 INR536.61B 44.23 20.35
LAURUSLABS:NSE Laurus Labs Limited

N/A

 INR348.25B 35.50 23.16
IPCALAB:NSE Ipca Laboratories Limited

N/A

 INR279.07B 24.41 17.04
NATCOPHARM:NSE NATCO Pharma Limited

N/A

 INR199.02B 45.18 26.80
AJANTPHARM:NSE Ajanta Pharma Limited

N/A

 INR186.93B 28.76 17.51

ETFs Containing ALKEM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.05% 35% F 26% F
Dividend Return 0.85% 33% F 40% F
Total Return 15.89% 37% F 27% F
Trailing 12 Months  
Capital Gain 36.36% 18% F 20% F
Dividend Return 1.12% 79% C+ 43% F
Total Return 37.49% 20% F 20% F
Trailing 5 Years  
Capital Gain 122.83% 65% D 74% C
Dividend Return 4.73% 92% A- 57% F
Total Return 127.56% 65% D 74% C
Average Annual (5 Year Horizon)  
Capital Gain 14.74% 48% F 63% D
Dividend Return 0.67% 77% C+ 68% D+
Total Return 15.42% 46% F 63% D
Risk Return Profile  
Volatility (Standard Deviation) 21.25% 100% A+ 94% A
Risk Adjusted Return 72.55% 64% D 93% A
Market Capitalization 406.46B 91% A- 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.64 56% F 46% F
Price/Book Ratio 5.50 36% F 19% F
Price / Cash Flow Ratio 32.13 31% F 17% F
EV/EBITDA 18.73 49% F 37% F
Management Effectiveness  
Return on Equity 23.33% 72% C- 88% B+
Return on Invested Capital 17.17% 68% D+ 86% B
Return on Assets 9.75% 70% C- 87% B+
Debt to Equity Ratio 0.46% 65% D 80% B-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.34 84% B 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.